Supreme Court Slams Medicine Price Markup as Extortion
India’s Supreme Court described the massive price gap between wholesale medicine costs and maximum retail prices as “carnage” and “broad daylight dacoity with patients,” prompting the central government to promise a regulatory fix.
Government Admits Pricing Flaws Before the Bench
Solicitor General Tushar Mehta acknowledged the pricing discrepancies on behalf of the Centre, stating that the administration would not take an adversarial stance and requested time to consult with officials on a solution, The Times of India reported. The bench pointed out that taxpayers ultimately bear the financial burden when corporate hospitals secure full reimbursement for inflated retail prices under government-sponsored welfare schemes like Ayushman Bharat, draining public funds.
NPPA Regulates Prices for Essential Medicines
Under the Drugs (Prices Control) Order (DPCO) of 2013, the National Pharmaceutical Pricing Authority regulates scheduled formulations listed under the National List of Essential Medicines. The current Schedule I contains 384 medicines, capturing roughly 20 percent of total drug market turnover, where the NPPA enforces a ceiling price by adding a maximum 16 percent retailer margin to the average price charged to retailers. Conversely, non-scheduled medicines remain outside these strict price caps, allowing manufacturers and private providers wider latitude in setting retail prices.
The Indian Express detailed how the NPPA calculates ceiling prices using market turnover data and manufacturer prices to retailers, while Kerala Kaumudi highlighted that many private hospitals require patients to purchase medications exclusively through in-house pharmacies at marked-up rates. Meanwhile, Moneycontrol.com noted that analysts calculate a profit margin cap could impact operating earnings of corporate hospitals by 1 to 5 percent.
Supreme Court Adjourns Hearing to October 12
Following the Centre’s request for consultations to balance equities and formulate a workable pricing policy, the Supreme Court adjourned the proceedings to October 12. The bench emphasized that all medications are fundamentally essential for patients and questioned the legal rationale behind maintaining rigid price controls for only a fraction of drugs while permitting elevated pricing across the broader pharmaceutical market.
Frequently Asked Questions About India’s Drug Pricing Scrutiny
Why did the Supreme Court call medicine pricing carnage?
The bench used the term after examining an essential cancer drug supplied to retailers for Rs 2,700 that carried a maximum retail price of nearly Rs 27,000, representing a tenfold markup.
What is the current retailer profit margin permitted under DPCO 2013?
The Drugs (Prices Control) Order, 2013, permits a 16 percent retailer margin over the average price charged to retailers when the National Pharmaceutical Pricing Authority calculates scheduled drug ceiling prices.
How many medicines are currently under government price control?
Schedule I of the DPCO contains 384 essential medicines based on the Ministry of Health and Family Welfare’s National List of Essential Medicines, accounting for about 20 percent of total drug market turnover.
When is the Supreme Court scheduled to hear the pricing petitions next?
The Supreme Court adjourned the hearings to October 12 to allow Solicitor General Tushar Mehta and government officials sufficient time to consult and propose a balanced regulatory solution.
Worth a look